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As infection rates decrease, much of Latin America seems to be taking a 
breather from the onslaught of COVID-19. However access to vaccines is 
unequal, both within and between individual countries, while vaccine cover-
age is heterogeneous. Combined with uneven infection rates and the arrival 
of the highly contagious Delta variant, new epidemiological and policy chal-
lenges must be addressed.
 • With 45 million registered infections and almost one-third of all COVID-19-relat-
ed deaths worldwide, Latin America has become a global hotspot in the pandemic. 
 • While Chile and Costa Rica have higher vaccination rates than Germany or the 
United States, half of Latin America’s population has yet to receive their first 
jab. What may come to the rescue are the high numbers of people who have ac-
quired some immunity from past COVID-19 infections beyond those identified 
in official statistics.
 • Vaccine diplomacy has changed colours. Initially, Latin America depended on 
vaccine shipments from China, India, and Russia. By now, the US and the mul-
tilateral COVAX initiative have become the largest providers. Policies will need 
to adjust to the resulting mix of vaccines of varying efficacy and varying inter-
national recognition. 
 • To reduce external dependence, the region will need to build up its capacity to 
develop and mass-produce vaccines, diagnostic equipment, and mRNA tech-
nology. The vaccines developed in Cuba could become part of the vaccine port-
folio the continent will need for many years to come.
 • The pandemic has exposed the region’s structural weaknesses. Public-health 
funding must be stepped up; ad hoc social-policy measures taken in the pandem-
ic should be harnessed to make social safety nets more resilient and inclusive.
Policy Implications
A strong vaccination drive remains key to keeping the pandemic at bay. As im-
munity – whether from past infection or vaccination – will eventually wane, 
vaccination may need to be integrated into routine preventive healthcare. 
Cooper ation transcending ideological left-right dichotomies in epidemiological 
diagnosis, research, vaccination, and healthcare provision must become a prior-
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The Latin American Drama: Is the Worst Over?
Despite being home to just 8.4 per cent of the world’s population, Latin America 
and the Caribbean has accounted for almost one-third of COVID-19-related deaths 
to date. This includes the world’s second-highest death toll on the country level 
(Brazil) and the world’s highest registered rate of deaths per capita (Peru; see 
Figure 1). The tragic milestone of a million deaths regionally was passed as early 
as May 2021. 
The horrendous death toll in Latin America and the Caribbean comes despite a 
popu lation with a median age of 31, and hence much younger than that of the Unit-
ed States (median age 38.5) or Europe (42.5). The case of Peru – which for years 
had some of the highest economic growth rates on the continent – highlights that 
the death toll is no mere function of gross domestic product. Instead, the pandemic 
has brutally exposed the region’s structural weaknesses: strained and underfunded 
healthcare systems, late and limited access to vaccines, deep-seated social inequali-
ties, extensive informal-labour practices, unhealthy diets leading to widespread 
obesity, insufficient state capacity, and incoherent policies have all contributed to 
this painful outcome. 
Beyond the epidemiological drama, the economic and social fallout from dis-
rupted global trade and travel as well as from lockdown measures has been enor-
mous, from steep economic decline, to psychological suffering, to lost educational 
potential. A recent study estimates that 22 million more people fell into poverty in 
the region in 2020, with a significant impact on children (ECLAC and PAHO 2021: 
3). It also stressed that in what is the world’s most unequal region “socioeconomic 
vulnerability is highly correlated with the severity of COVID-19 infection and mor-
tality” (ECLAC and PAHO 2021: 18). 
The COVID-19 pandemic has also shown that early advances are not the same as 
long-term success. Israel, the United Kingdom, and the US had been frontrunners 
in the vaccination drive; by late 2021, however, not only have their vaccination rates 
become stagnant but their COVID-19 infections per capita are higher than those of 
South America. Certainly, significant undercounting due to insufficient testing or 




Deaths per Million 
People, 19 October 
2021
Limited testing and 
challenges in the at-
tributuion of the cause 
of death means that the 
number of confirmed 
deaths may not be an ac-
curate count of the true 
number of deaths from 
COVID-19.
Source: Our World in 
Data 2021.
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and the US infection rates have gone up since summer 2021, in South America re-
ported infection, hospitalisation, and death rates have all been in decline. There are 
three main factors likely explaining this trend: 
 • The seasonal effect, since the Southern Hemisphere is now past winter season. 
 • The progress of vaccination campaigns. Most Latin American countries have 
by now attained vaccination coverage rates of around 30 to 60 per cent of their 
populations, which is far higher than in other tropical regions such as sub-Sa-
haran Africa. 
 • A large share of the population have acquired some level of immunity from hav-
ing experienced infection, whether diagnosed or not.
However, the highly contagious Delta variant of SARS-CoV-2 – a so-called variant 
of concern (VOC) which has swept most of the world already – is only now making 
its full entry into South America. It arrived earlier this summer in the Caribbean, 
which in its wake would see soaring infection rates. Barbados currently tops global 
tables with a seven-day incidence rate of more than 700 infections per 100,000 
people. 
So how much light is there at the end of the tunnel for Latin America? Is the 
worst over, really? To tackle this question we look at the uneven vaccination process 
in the region; at the heterogenous levels of past infections conferring some level of 
immunity; at the delayed arrival of the Delta variant in parts of the region; and, at 
the complex mix of vaccines applied and the implications hereof. We then address 
the need to strengthen pandemic preparedness to overcome external dependence, 
before finally identifying necessary steps towards rectifying the societal and eco-
nomic damage the pandemic has wreaked regionally.
Large-Scale but Uneven Vaccination 
The absolute scarcity of vaccines marking the initial phase of the pandemic has 
since given way to a highly uneven process of vaccination in the region – between 
countries, within countries, and also with regards to the types of vaccines avail-
able. In the last few months, almost all Latin American countries have significantly 
advanced their vaccination programmes (see Figure 2 below). But it is worth distin-
guishing between three sub-regions here: 
 • Across South America, almost two-thirds of the population have received at 
least their first shot; only Venezuela’s vaccination rate is below the global aver-
age. 
 • In Central America the picture is mixed: significant progress in Costa Rica, El 
Salvador, and Panama; low vaccination rates in Guatemala, Honduras, and 
Nicaragua; in Mexico, a middle ground has been reached, being almost on par 
with Colombia and Peru but clearly below South America’s leaders Argentina, 
Brazil, Chile, and Uruguay.
 • In the Caribbean, initially clever vaccine diplomacy made a number of states 
vaccination pioneers (Hoffmann 2021). However, these campaigns soon stag-
nated; by now, vaccination rates largely trail behind those on the Latin Ameri-
can mainland. Cuba is a notable exception: it started vaccination later than 
 others, but almost 90 per cent of the population have received at least a first 
dose.
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In many places, vaccine availability is still a bottleneck. Another issue – also 
very unevenly distributed – is vaccine hesitancy. In Brazil, for instance, public-
health institutions have a long-standing reputation for social progress, and over 
the decades vaccinations have acquired broad acceptance. This has prevailed over 
social media disinformation and the negationist attitude of the federal government. 
The metropoles Rio de Janeiro and São Paulo by now boast higher vaccination rates 
than Berlin or New York.
Nevertheless in other countries, including many in the Caribbean, health authori-
ties are battling with vaccine scepticism, even as the Delta variant sweeps the region 
with force. In the small island state of Dominica, for instance, as early as 1 April 2021 
some 25 per cent of the population had received their first jab, putting the coun-
try at the vanguard. However since then the vaccination campaign has advanced 
at snail’s pace: standing at less than 35 per cent by 1 October 2021. Dr. Carissa 
Etienne, Director of the Pan American Health Organization (PAHO) and herself a 
native of Dominica, recently noted: “Even when vaccines are available, persons are 
not coming forward” (PAHO 2021).
In Jamaica, the vaccination rate is lower still. Less than 10 per cent of the 
population have been fully vaccinated. According to one 2020 survey, 72 per cent 
of Jamaicans reportedly said they would not accept a COVID-19 vaccine (cited in 
CARPHA 2021: 2). However, surveys fail to provide satisfactory explanations. In 
the one carried out by the Caribbean Public Health Agency, respondents most often 
offered the standard answers: that they were concerned about possible side effects; 
did not know enough about the vaccine; thought the vaccine was developed too 
quickly (CARPHA 2021: 11). But in none of this – nor in its exposure to social media 
– does the region differ from the rest of the world. Instead, it seems likely that part 
of the mistrust is rooted in a history of racialised, colonial public health – including 
unethical healthcare research among Afro-descendent populations. 
Figure 2 
Share of People 
Vaccinated against 
COVID-19 in Latin 
American and Carib-
bean Countries, 18 
October 2021 
Alternative definitions 
of a full vaccination, e.g. 
having been infected 
with SARS-CoV-2 and 
having 1 dose of a 2-dose 
protocol, are ignored to 
maximise comparability 
between countries.
Source: Our World in 
Data 2021.
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The Delayed Entry of the Delta Variant 
Since this summer the Delta VOC’s predominance has been observed globally, how-
ever not (yet) in all of South America. In Colombia the Mu variant still dominates, 
in Bolivia the Gamma variant, while in Peru the Lambda variant maintains a strong 
presence. Whether these have delayed the rise of the Delta variant or whether its 
late introduction is simply a matter of reduced international connectivity remains 
a matter of debate. Nonetheless, there is little doubt that the increased transmis-
sibility of the Delta variant will lead to its dominance in those countries eventually.
In Mexico, where the Delta variant became dominant over the course of this 
summer, COVID-19 infection rates have gone up – but not dramatically, and not 
for long. Argentine health minister Carla Vizzotti warned that it will be impossible 
to prevent the Delta variant from circulating in the country; indeed, it has come to 
represent 50 per cent of cases in the latest samples. In Brazil, many feared that the 
Delta variant would produce another wave of devastation in a country which has 
already mourned 600,000 dead. However, even with the Delta variant fully domi-
nating by now and despite a relaxing of social-distancing measures so far no major 
increase in infection rates has been seen. 
This is all the more remarkable as in the Caribbean the picture is the absolute 
opposite. The latter had passed impressively lightly through the early waves of the 
pandemic compared to mainland Latin America. However, this changed when the 
Delta VOC reached the Caribbean’s islands this summer. The first country hit was 
Cuba, where spiralling infection rates brought the island’s healthcare system to the 
brink of collapse. More recently, it has been the island states of the anglophone 
Caribbean seeing an explosion of cases – battering their healthcare systems and 
putting them among the countries with the world’s highest per capita incidences of 
infection (Figure 3). 
Partial Immunity through Past Infection
So what explains these regional differences? Combined with insufficient vaccination 
rates, the crucial difference is probably the Caribbean’s comparatively low exposure 
to the virus in the first year and a half of the pandemic. In both Central and South 
Figure 3 
Daily New Confirmed 
COVID-19 cases per 
Million People, Se-
lected Latin Ameri-
can and Caribbean 
Countries, 19 October 
2021
Shown is the rolling 
7-day average. The num-
ber of confirmed cases is 
lower than the number 
of actual cases; the main 
reason for that is limited 
testing. "South America" 
includes Brazil and Peru, 
but not Central America 
and Mexico.
Source: Our World in 
Data 2021.
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America in contrast, the raging pandemic left hundreds of thousands dead, and 
millions infected. Brazil, for instance, has reported almost 20 million confirmed 
cases as of October 2021, more than 10 per cent of the country’s total population. 
This may just be the tip of the iceberg, given the high proportion of asymptomatic 
or mild infections (estimated at around 80 per cent in most studies) and low testing 
capacities. In consequence, it is very likely that in Brazil – as in many other Latin 
American countries too – COVID-19 infections have been much more widespread 
than official data can capture. 
The rate of undetected infections will be particularly high among the young, as 
well as in rural and poor urban settings where insufficient healthcare infrastruc-
tures likely intersect with test avoidance since mandatory quarantine is perceived 
as incompatible with the income imperatives of day labourers or street vendors. 
Consequently, past COVID-19 infections have mediated partial immunity, comple-
menting the advent of vaccine programmes – but at a desperate cost in terms of 
both individual suffering and societal disruption. 
The way to know more about the pervasiveness of past infections is studies on 
“seropositivity” – that is, blood analyses showing antibodies from past infections no 
matter whether one was symptomatic or not, and regardless of whether the case was 
reported or not. Unfortunately, such studies are not systematically available for the 
whole continent. But some case studies do show high rates of “hidden infections.” 
For instance, a March 2021 study in northern Peru’s San Martín region showed 
an overall 59.0 percent seroprevalence, diverging substantially from reported in-
cidence (Moreira-Soto et al. 2021). However, earlier studies from 2020 reporting 
stunning seroprevalence rates of around 70 per cent from Iquitos in the Peruvian 
Amazon (Alvarez-Antonio et al. 2021) or Manaus in the Brazilian Amazon (Buss 
et al. 2021) have to be taken with caution. Antibody tests used in Latin America 
frequently are neither designed nor validated for usage in tropical regions and can 
lead to false positives, as shown in Moreira-Soto et al. (2021) and Yadouleton et al. 
(2021) (Drexler a co-author in both). This may in part explain renewed outbreaks in 
Iquitos and Manaus, when some thought herd immunity had already been reached. 
Despite these caveats, in Latin America (partial) immunity likely not only 
comes from vaccination but also from the high rates of those who have experienced 
COVID-19 infection – symptomatic or not, detected or not. [1] This also helps to 
explain why the arrival of the Delta variant has caused such havoc in the Caribbean: 
Here, initially, the pandemic had been kept at bay better than elsewhere. Dominica, 
for instance, did not have to report a single fatality for more than a year and a half 
after the outbreak of the pandemic, and other anglophone island states had simi-
larly impressive low infection and death rates. 
Precisely because of that success, in the Caribbean the Delta variant encoun-
tered a population in which only the vaccinated had some immunity, and very few 
of the non-vaccinated. It should be noted that, luckily, across all of Latin America 
and the Caribbean high numbers of infections do not translate into similarly high 
fatality rates as those witnessed during the early phases of the pandemic. This is due 
to increased vaccination of the elderly and other at-risk population strata.
1 Recent studies show 
that the combination of 
infection then followed 
by an mRNA vaccine 
being administered brings 
especially good protec-
tion – also against new 
variants like Delta (Schmidt 
et al. 2021).
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A Complex Mix of Vaccines
Understanding the course of the pandemic also requires scrutinising which vac-
cines have been used in the region. They can be split into four categories: 
 • The vectored vaccines like those from AstraZeneca, Johnson & Johnson, or the 
Russian Sputnik (adenovirus vectors carrying the gene encoding the spike sur-
face protein of the new coronavirus) 
 • The mRNA vaccines like those from Pfizer/BioNTech and Moderna (a modified 
messenger RNA encoding the spike protein) 
 • The inactivated vaccines like SinoVac and Sinopharm (relying on cultivated 
SARS-CoV-2 that is chemically inactivated, for example by formaldehyde) 
 • The protein-subunit-based vaccines like both of Cuba’s, Abdala and Soberana 
(relying on the receptor-binding domain of the spike protein, in the case of So-
berana coupled to tetanus toxoid to increase immunogenicity).
Each of these vaccine formulations has its advantages and disadvantages in the 
Latin American context. The mRNA vaccines have shown extremely high efficacy in 
preventing disease, but require storage at very low temperatures. During the early 
days of the pandemic, those mRNA vaccines were neither available to nor logisti-
cally manageable in most countries of the region. Sputnik was offered by the Rus-
sian authorities early on, but geopolitical negotiations limited availability and did 
not allow widespread usage in the region. Inactivated vaccines produced in China 
were available and affordable and thus formed the backbone of the early vaccina-
tion programmes. Both Cuban vaccines rely on relatively simpler technology, and 
as such they are fairly easy to produce, to store, and to administer – even if they 
require multiple shots each.
All these vaccines thus afford some protection against COVID-19, but at dif-
ferent levels of efficacy. In the Latin American context, this became clearest when 
Chile – which until then had 93 per cent reliance on the SinoVac vaccine – suffered 
yet another wave of infections this April despite what was back then Latin America’s 
highest vaccination coverage (50 per cent of the population having received at least 
one dose). This may well be associated with relatively lower efficacy of inactivated 
vaccines due to changes in protein structure caused by the chemicals used for vi-
rus inactivation, affording reduced immunogenicity. To contain this deadly wave 
the country had to return to non-pharmaceutical interventions such as lockdown 
measures, which in turn contributed to the severe economic crisis the country – as 
all of Latin America – has been suffering in the wake of the pandemic. As of late 
2021, mRNA and vectored live vaccines have become more widely available and 
most countries have come to using a broad spectrum of vaccine formulations, mix-
ing them successfully. 
Vaccines: From Donations to Domestic Production
During 2020 and early 2021, Europe and the US secured the bulk of the vaccines 
produced by Western companies for their own populations, with most countries in 
Latin America turning to China, India, and Russia instead. Over time, however, vac-
cine diplomacy has changed colours. With its domestic vaccination campaign hav-
ing stagnated, Washington is passing on millions of excess doses to other countries. 
   8    GIGA FOCUS | LATIN AMERICA | NO. 5 | OCTOBER 2021 
The US has by now become the prime vaccine donor to Latin America (Harrison 
2021). Beyond donations, Latin American countries have also sought direct pro-
curement from producers as well as acquisition via the multilateral COVAX facility 
in its different forms.
COVAX, to which Europe, the US, and other developed nations pledged bil-
lions of euros, initially got off to a slow start. For supplies, it largely relied on In-
dia’s vaccine production; with the latter’s own massive COVID-19 outbreak in April, 
however, all vaccine exports were halted to cater to domestic demand first. Even if 
COVAX, working together with the PAHO, has distributed more than 20 million 
vaccine doses to Latin America and the Caribbean this is still far below what was 
originally planned and pledged. Despite deliveries now increasing, disappointment 
with COVAX still weighs heavily throughout the region. One consequence is that the 
PAHO has struck separate deals to buy millions of Chinese Sinopharm and Sinovac 
vaccine doses, as well as AstraZeneca ones too.
Initiatives for the local development of COVID-19 vaccines or the licenced pro-
duction of existing vaccines have proven to be more complex than initially hoped. 
However, a Mexican-Argentine collaborative project with AstraZeneca reported to 
have shipped its first batch of a million locally produced vaccines to Argentina, Be-
lize, Bolivia, and Paraguay in June 2021 (Navarro 2021). Cuba’s vaccines are a dif-
ferent case besides, as they are not produced under licence from international com-
panies but are original developments by the island’s biotech sector – a remarkable 
accomplishment given the economic constraints of the country and the fact that 
much richer states and deep-pocketed global pharma companies failed to achieve 
this. 
However, as mass production of the vaccine took longer than planned, the is-
land started its vaccination campaign late – paying a heavy price for that. The arrival 
of the Delta variant in June 2021 led to a surge of infections wreaking havoc on the 
Cuba’s healthcare sector, traditionally the country’s pride. If Cuba initially gained 
international repute by sending doctors and health workers abroad to fight the pan-
demic, it now had to seek medical and other humanitarian support from outside.
While Cuba’s vaccines have yet to receive World Health Organization recogni-
tion, they have stood the test of practical implementation. Once the island’s vac-
cination campaign got under way it gradually brought the curve of infections down. 
Efficacy in the face of the Delta variant may eventually be less than the 90 per cent 
officially announced following clinical trials, but the Cuban vaccines have clearly 
been instrumental in getting the pandemic under control. 
Cuba also became the world’s first country to vaccinate children aged two and 
over. By the end of 2021, the island will likely have fully vaccinated 90 per cent of 
its population. With domestic demand covered, first shipments of Cuban vaccines 
have been exported to Venezuela and Vietnam. While they probably will not get 
recognition in Europe or the US any time soon, Cuban vaccines can be a helpful 
low-cost addition in the vaccination campaigns in Latin America, and in the Global 
South more generally. 
However, Latin America will also need to expand its own capacity to develop 
and produce vaccines. The PAHO has selected two biomedical centres in Argentina 
and Brazil as regional hubs to develop and produce mRNA vaccines. [2] In mid-
October 2021 Mexico signed a deal with Russia to produce the Sputnik vaccine in 
state laboratories. Pfizer/BioNTech announced commencing production together 
 
2 In Brazil, this is the Bio-
Manguinhos Institute of 
Technology on Immuno-
biologicals at Fiocruz, the 
country’s premier biomedi-
cal laboratory; in Argentina, 
Sinergium Biotech, a pri-
vate sector biopharmaceu-
tical company. 
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with Brazil’s Eurofarma corporation, with at least 100 million doses annually pro-
jected for distribution in the region (Burger and Mishra 2021). 
What Is to Be Done?
It may be that most of Latin America indeed has passed through the worst: The 
drama of infections spiralling out of control, hospitals being overrun, and a death 
toll measured in the hundred thousands may not see a repeat. However we do not 
know if new SARS-CoV-2 mutations will continue to thrive among partially immune 
populations, as some studies suggest (Baj et al. 2021). There is much about the new 
coronavirus we do not yet fully understand.
Regardless, the pandemic is far from over. It will have lasting effects on 
 people’s health still difficult to assess. Non-pharmaceutical interventions – from 
mask-wearing to social-distancing measures – are likely to still be indispensable 
in many places. Opening up once again to travel and tourism entails the risk of 
reinvigorating infection curves. Moreover, the pandemic has created economic and 
social disruptions, sharpened socio-economic inequalities, increased gender-based 
violence, and brought about a range of other consequences that also weigh heav-
ily on the region’s future. Not only Latin America’s healthcare systems but, more 
broadly, the region’s societies and economies will be struggling with COVID-19 for 
years – if not decades – to come. 
What we do know: immunity – whether through vaccination, past infection, or 
the combination of both – will not last forever. In the case of yellow fever, childhood 
infection gives permanent immunity, and the effect of a single-shot jab is thought 
to last a lifetime. In contrast, COVID-19 immunity will wane sooner or later. Since 
we know this, we can prepare for it in advance. Vaccination boosters will have to 
become part of routine healthcare provision if we are to avoid new rounds of deadly 
outbreaks – and the policy measures needed to cope with them. 
New medication is being developed, but as of now no magic bullet is in sight. 
Molnupiravir, which recently sought emergency-use authorisation in the US, may 
reduce the risk of hospitalisation or death significantly, but only if infection is de-
tected at an early stage and medication is swiftly administered. Additionally, the 
drug’s safety profile is not fully understood yet. As with previous vaccines, rich 
countries may secure the first produced batches for themselves, and prices will like-
ly be prohibitively high for much of Latin America’s population. 
The pandemic has exposed crucial structural weaknesses that Latin American 
countries will need to address if they are to fare better in the future:
 • The chronic underfunding and dysfunctional structures of the public-health 
systems need to be overcome so that they can provide effective healthcare ser-
vices to the citizenry at large, not only to the well-off. 
 • The region will need to build up the ability to develop and mass-produce own 
vaccines, diagnostic equipment, and mRNA technology to reduce dependence 
on foreign providers. 
 • Cooperation and scientific exchange within the region need to become swifter 
and better institutionalised, be it as part of or as complement to existing supra-
national schemes. 
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 • As vaccines are being produced in the region, trade in them should be eased. 
The Cuba-made vaccines should not be seen per ideological but rather per med-
ical criteria. As such, they can form a vital part of the vaccine portfolio that the 
continent will need for many years to come.
 • Ad hoc social-policy measures that helped significantly expand coverage (Blo-
field et al. 2020) should not be shelved as soon as the sense of emergency re-
cedes, rather seen as an opportunity to make permanent social safety nets more 
resilient and inclusive.
 • The severe drops seen in GDP and living standards need to be reversed by poli-
cies that indeed live up to the promise of “building back better” – that is, ones 
leading to more equitable and sustainable economies.
 • The pandemic has also underscored the importance of political stability, of per-
sonal integrity, and of a fact-based public discourse beyond short-term partisan 
gains or open disinformation. 
International cooperation with actors from outside the region will continue to be 
important in many ways. In the early phases of the pandemic, COVAX fell short of 
expectations; as global vaccine production increases, however, it can be a key con-
tributor to broad and equitable access to vaccines. This is true not only in the acute 
current crisis but also the near future. COVAX has the potential to bridge political 
divides that in times of a pandemic should step aside. For instance, the initiative 
has provided vaccines to Venezuela simultaneous to the US government explicitly 
excluding that country from its bilateral vaccine donations. 
Research on COVID-19 and, more broadly, on infectious diseases is a task that 
needs strong engagement in transnational scientific cooperation and exchange. 
This includes pooled funding for joint research endeavours but also support for lab 
infrastructure and diagnostic capacities throughout Latin America. One such initia-
tive is the “German-Latin American Centre of Infection & Epidemiology Research 
and Training” (GLACIER), in which both authors are involved and which aims at 
facilitating mutual learning and knowledge-sharing between universities and re-
search centres in Germany, Cuba, Mexico, and throughout Central America.
Swiss author Friedrich Dürrenmatt, in the epilogue to his 1962 drama The Phys-
icists, famously posited: “What concerns all, only all can solve. Each individual at-
tempt to solve in isolation what concerns all must fail.” There is no national solution 
to a pandemic. As long as SARS-Cov2 remains unchecked in any part of the globe it 
will continue its process of mutation – potentially putting at risk the effectiveness of 
vaccinations and other measures. The fight against infectious diseases – and, more 
broadly, for global public health – is, then, a concern which “only all can solve.” 
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